Joulferon: Withdrawal of the marketing authorisation application
Table of contents
Overview
On 16 April 2010, Novartis Europharm Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Joulferon, for the treatment of hepatitis C infection.
Key facts
Name |
Joulferon |
Product number |
EMEA/H/C/002166 |
Date of withdrawal |
16/04/2010 |
Company making the application | |
Withdrawal type |
Initial authorisation |
All documents
-
List item
Withdrawal letter: Joulferon (PDF/54.41 KB)
First published: 29/04/2010
Last updated: 29/04/2010 -
List item
Novartis Europharm Ltd withdraws its marketing authorisation application for Joulferon (albinterferon alfa-2b) (PDF/55.57 KB)
First published: 19/04/2010
Last updated: 19/04/2010
EMA/249301/2010 -
List item
Questions and answers on withdrawal of marketing authorisation application for Joulferon (PDF/102.2 KB)
First published: 29/04/2010
Last updated: 29/04/2010 -
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').